Hypermethylation-mediated tumor suppressor gene (TSG) silencing is a central epigenetic alteration in RAS-dependent tumorigenesis. Ten-eleven translocation (TET) enzymes can depress DNA methylation by hydroxylation of 5-methylcytosine (5mC) bases to 5-hydroxymethylcytosine (5hmC). Here we report that suppression of TET1 is required for KRAS-induced DNA hypermethylation and cellular transformation. In distinct non-malignant cell lines, oncogenic KRAS promotes transformation by inhibiting TET1 expression via the ERK signaling pathway. This reduces chromatin occupancy of TET1 at TSG promoters, lowers levels of 5hmC, and increases levels of 5mC and 5mC-dependent transcriptional silencing. Restoration of TET1 expression by ERK pathway inhibition or ectopic TET1 reintroduction in KRAS-transformed cells reactivates TSGs and inhibits colony formation. KRAS knockdown increases TET1 expression and diminishes colony-forming ability, while KRAS/TET1 double knockdown bypasses the KRAS dependence of KRAS-addicted cancer cells. Thus, suppression of TET1-dependent DNA demethylation is critical for KRAS-mediated transformation.
Introduction
RAS proteins are a family of 21 kDa proteins that accomplish signal transduction by coupling receptor engagement to downstream pathway activation (Pylayeva-Gupta et al., 2011) . RAS proteins, which include KRAS, HRAS and NRAS, share similar functions in regulating cell proliferation, differentiation and survival. Gain-of-function mutations in RAS genes are found frequently in malignancies (D'Arcangelo and Cappuzzo, 2012; Pylayeva-Gupta et al., 2011) , and multiple malignancies depend on RAS mutations to maintain malignant phenotypes (Chin et al., 1999) . Hyperactive RAS drives constitutive signaling through the RAF-MEK-ERK and PI3K-AKT cascades (Schubbert et al., 2007) driving cellular transformation (Greig et al., 1985) . Accordingly, targeting RAS-related signaling pathways is a central goal of molecular oncology (Downward, 2003) .
Cytosine methylation of CpG dinucleotides is an epigenetic modification that cells use to regulate gene expression, largely to promote transcriptional silencing. Focal hypermethylation of tumor suppressor genes (TSGs) accompanied by genomic hypomethylation are epigenetic hallmarks of malignancy (Belinsky, 2004; Jones and Baylin, 2002; . Three DNA methyltransferases (DNMTs), the de novo enzymes DNMT3A and DNMT3B and the maintenance enzyme DNMT1, are responsible for establishment and maintenance of DNA methylation patterns (Bestor, 2000) . Aberrant overexpression of DNMTs contributes to cancer-associated DNA hypermethylation (Belinsky et al., 1996; Wu et al., 1993) . Inhibition of DNMTs in cancers can revert DNA hypermethylation, reactivate silenced TSGs and diminish tumorigenicity (Laird et al., 1995; Suzuki et al., 2004) , indicating that DNA methylation is reversible by modulating DNMT activities.
Previous studies showed that RAS-driven transformation drives methylation-associated silencing of TSGs to inhibit apoptosis and promote cell proliferation (Borrello et al., 1987; Gazin et al., 2007; Patra, 2008; Serra et al., 2014) . RAS activation was shown to trigger DNA hypermethylation through elevated DNMT transcription (Bakin and Curran, 1999; Chang et al., 2006; Gazin et al., 2007; Pruitt et al., 2005) and the initiation of what has been termed an elaborate pathway involving components of the RAF-MEK-ERK and PI3K-AKT cascades that positions Dnmt1 on particular TSG promoters such as Fas (Gazin et al., 2007) . In addition, inhibition of DNMT expression has been shown to be sufficient to reverse RASinduced hypermethylation and transformation (MacLeod and Szyf, 1995; Ramchandani et al., 1997) . Thus, DNMT enzymes have been considered the principal mediators of DNA methylation driven by RAS activation and have been targeted by early stage drug discovery efforts (Fagan et al., 2013a; 2013b; Huang et al., 2013) . While positively acting factors that promote Ras-dependent DNA methylation have been identified by genetic selections (Gazin et al., 2007; Serra et al., 2014) , factors that must be inhibited for Ras-driven DNA methylation remain elusive.
Recent findings demonstrated that the ten-eleven translocation (TET) family proteins, including TET1, TET2 and TET3, function as iron and α-ketoglutarate-dependent 5methylcytosine dioxygenases that convert 5-methylcytosine (5mC) bases to 5hydroxymethylcytosine (5hmC) bases (Ito et al., 2010; Tahiliani et al., 2009 ). 5hmC is proposed as an intermediate in passive and active DNA demethylation (Kohli and Zhang, 2013; Pastor et al., 2013; Wu and Zhang, 2014; , suggesting novel mechanisms to regulate methylation dynamics and gene reactivation. Presence of 5hmC in genomic DNA impairs maintenance methylation by preventing DNMT1 recognition (Hashimoto et al., 2012; Valinluck and Sowers, 2007) , thereby facilitating passive demethylation linked to the semiconservative nature of DNA replication. In addition, 5hmC can be further converted by TET proteins to 5-formylcytosine (5fC) and 5-carboxycytosine (5caC) (Ito et al., 2011) , which are replaced by cytosine through DNA repair processes (Cortellino et al., 2011; and may play roles in gene expression apart from demethylation. TET-mediated active demethylation is independent of DNA replication (Pastor et al., 2013; Wu and Zhang, 2010) .
TET proteins and 5hmC modifications are abundant in mouse embryonic stem cells (ESC) (Ficz et al., 2012; Ito et al., 2010; Koh et al., 2011) and in the brain (Guo et al., 2011; Kaas et al., 2013; Kriaucionis and Heintz, 2009 ). In addition to the roles of TET-driven DNA modification in ESC and neuronal systems, emerging evidence suggests that TET-dependent DNA demethylation plays a role in tumorigenesis. In solid tumors, expression of TET genes is dramatically reduced and is highly associated with reduced 5hmC (Ko et al., 2010; Lian et al., 2012; Yang et al., 2013) and hypermethylation-mediated silencing of TSGs (Hsu et al., 2012; Sun et al., 2013) . Moreover, TET2 is frequently mutated with impaired catalytic activity in myeloid cancers (Abdel-Wahab et al., 2009; Delhommeau et al., 2009; Ko et al., 2010) . These data suggest that TET genes themselves may have TSG activity. However, whether TET-mediated DNA demethylation plays a role in RAS-induced DNA hypermethylation and malignant transformation remains unclear.
In this study, we used two non-malignant cell lines to dissect KRAS-driven transformation and the establishment of cancer-associated DNA hypermethylation. Unexpectedly, instead of an increase in DNMT expression, we discovered that TET1 is transcriptional suppressed via the RAS-ERK signaling pathway. Regional decreases in 5hmC were accompanied by TSG promoter hypermethylation and gene silencing. Forced TET1 reintroduction not only reactivated silenced TSGs but also abolished KRAS-induced colony-forming ability. Moreover, KRAS depletion by small interfering RNA (siRNA) up-regulated TET1 expression in cancer cells. Strikingly, knocking down TET1 restores colony-forming ability to KRAS depleted cells, indicating that TET1 suppression is sufficient to maintain KRAS transformation several steps downstream from KRAS. These data establish that impaired TET1-mediated DNA demethylation is a critical mediator of tumor initiation and maintenance in KRAS-transformed cells.
Results

Oncogenic KRAS Expression is Sufficient to Transform Non-Malignant HBEC3 Cells
Expression of KRAS-G12V has the ability to transform a broad spectrum of non-malignant cells (Patra, 2008; Pylayeva-Gupta et al., 2011) . However, a previous report showed that overexpression of KRAS-G12V was insufficient to transform immortalized human bronchial epithelial cells (HBEC3), apparently due to lack of induction of downstream signals (Sato et al., 2006) . To probe the biological effect of oncogenic KRAS in HBEC3 cells, we established stable cell lines with KRAS-G12V marked by an N-terminal myc-tag. After serial dilution to select monoclonal cell lines, three KRAS clones (R1, R2 and R3) and two vector control clones (V1 and V2) were selected and examined by western blot ( Figure 1A ). In R1, R2 and R3 cells, expression of myc-KRAS was about 30% of the level of endogenous RAS proteins. However, as shown in Figure 1A , expression of KRAS-G12V was associated with activation of AKT and ERK as evidenced by a 2-fold induction of phospho-AKT and 6-fold induction of phospho-ERK.
We found a 23% increase in cell proliferation in KRAS cells under growth factor-rich conditions ( Figure 1B ). Additionally, because KRAS is an effector of epidermal growth factor (EGF) receptor signaling (Sharma et al., 2007; Yarden and Sliwkowski, 2001) , we considered whether expression of hyperactive KRAS could enable bypass of EGFdependent growth of HBEC3 cells (Sato et al., 2006 ) ( Figure 1B ). Without EGF supplementation, vector cells lost half their proliferation ability. However, KRAS cell lines without EGF supplementation showed the same extent of proliferation as vector cells with EGF, indicating a KRAS-mediated bypass. To further evaluate the oncogenic properties of KRAS cells, adherent and soft-agar colony formation were assessed. As shown in Figure  1C , adherent colony formation was increased 6-fold in KRAS cells while soft-agar colony formation in the presence of EGF was increased more than 100-fold. Without EGF supplementation, KRAS cells produced more than 10 colonies while vector cells produced none. In summary, HBEC3 cells can be used to dissect hyperproliferation, EGFindependence and colony formation driven by KRAS mutation.
Oncogenic KRAS Expression Causes Hypermethylation-Mediated Silencing of TSGs and Loss of Imprinting
Aberrant DNA methylation is a hallmark of cancer and RAS activation has been shown to drive DNA hypermethylation during tumorigenesis (Bakin and Curran, 1999; Chang et al., 2006; Gazin et al., 2007; Pruitt et al., 2005) . Although there was no increase in 5mC content in KRAS-transformed cells (Figures 2A and S1A ), we surveyed 24 TSGs reported to be silenced by promoter hypermethylation in lung cancers (Belinsky, 2004) (Table S1 ) by quantitative methylated DNA immunoprecipitation (MeDIP). An increase in promoter methylation was found in five of the 24 TSGs in KRAS cells, including DAPK (Kim et al., 2001) , MGMT (Pulling et al., 2003) , DUOX1 (Luxen et al., 2008) , TIMP3 (Bachman et al., 1999) and GATA4 (Guo et al., 2004) (Figures 2B and S1B). Bisulfite sequencing indicated 2 to 20-fold methylation increases in the promoters of DAPK, MGMT and DUOX1 in R2 cells in comparison to V1 cells ( Figure 2C ), demonstrating that KRAS activation caused DNA hypermethylation of specific TSGs. Because promoter hypermethylation is highly associated with transcriptional silencing, we analyzed expression of the five target genes. As shown in Figures 2D and S1C, the mRNA levels of all five genes were markedly decreased in KRAS cells.
In addition to hypermethylation of TSGs, loss of imprinting is an additional type of dysregulated methylation in malignancies. We focused on the well-studied H19 imprinting control region (H19 ICR) (Steenman et al., 1994) to examine the methylation change associated with KRAS activation. Bisulfite sequencing indicated that the methylation level of H19 ICR was increased from 40.7% in V1 cells to 65.9% in R2 cells ( Figure S1D ). Hypermethylation of H19 ICR was accompanied by silenced H19 and activated IGF2 expression ( Figure S1E ).
To test whether promoter hypermethylation was sufficient to suppress gene expression and whether methylation-associated gene silencing was reversible, we treated cells with the demethylating agent, 5-aza-deoxycytidine (5-aza-dC) (Jones et al., 1982 ) ( Figure S1F ). As shown in Figures 2E and S1G , 5-aza-dC reactivated expression of all five TSGs and reverted expression of H19 and IGF2, indicating that transcriptional silencing is driven by promoter hypermethylation and is reversible. In addition, 5-aza-dC pre-treatment decimated colony formation in KRAS-transformed cells compared to DMSO treatment ( Figure 2F ). Thus, HBEC3 cellular transformation depends upon an altered methylation status that is commonly found in human cancers.
KRAS Negatively Regulates TET1 Expression through the ERK Signaling Pathway
DNMT enzymes, especially DNMT1, are considered the major positive effectors of RASinduced hypermethylation (Gazin et al., 2007; Patra, 2008 ). Thus, we tested whether levels of DNMT1 were increased in KRAS cells. However, we did not observe any difference of DNMT1 expression between vector and KRAS cells at the mRNA or protein levels ( Figure  3A) . We further examined the other two DNA methyltransferases, DNMT3A and DNMT3B ( Figure S2A ). There was a slight decrease in DNMT3B expression in KRAS cells, which would not be expected to cause DNA hypermethylation. In addition to increased expression of one or more DNA methyltransferases, another possible mechanism to cause hypermethylation is suppression of enzymes that act on 5mC substrates, such as TET1, TET2 and TET3. As shown in Figures 3A and S2A , KRAS activation nearly extinguished expression of TET1 at the mRNA and protein levels. No change was observed in TET2 and TET3 expression.
RAS activation drives two major protein kinase cascades, namely the PI3K/AKT and RAF/MEK/ERK cascades. To dissect the mediator of TET1 extinguishment by KRAS, we used specific inhibitors of PI3K and MEK. Because these signals are essential for cell survival, we used low doses, i.e., 2 μM PI3K inhibitor LY294002 (Vlahos et al., 1994) or 30 μM MEK inhibitor PD98059 (Dudley et al., 1995) to titrate KRAS signaling without reducing cell viability ( Figure S2B ). As shown in Figure 3B , TET1 expression in KRAS cells treated with the MEK inhibitor was restored to the same level as in vector cells. However, no effect was observed after partial inhibition of PI3K. Moreover, DNMT1 expression was not altered by either inhibitor ( Figure 3B ). Remarkably, ERK pathway inhibition caused up to 3-fold transcriptional increases of DAPK, MGMT, DUOX1 and H19 in KRAS cells (Figures 3C and S2C) . Because epigenetic silencing of TSGs is essential for KRAS-mediated transformation in HBEC3 cells, we tested whether KRAS-mediated transformation was also regulated by one or the other kinase cascade. KRAS cells pretreated with PD98059 or LY294002 for 6 days were subjected to adherent and soft-agar colony-forming assays. As shown in Figure 3D , ERK pathway inhibition significantly reduced colony-forming abilities of KRAS cells, while AKT pathway inhibition had no effect. Together, our data indicate that KRAS decreases TET1 transcription and promotes cellular transformation through the ERK pathway.
Reduction of TET1 and 5hmC are Responsible for KRAS-Mediated DNA Hypermethylation and Cellular Transformation
To clarify the consequence of TET1 reduction in KRAS cells, we examined 5hmC levels in the genome. Though there was no dramatic change in genomic 5hmC in vector and KRAS cells ( Figures 4A and S3A) , we used 5-hydroxymethylcytosine DNA immunoprecipitation (hMeDIP) to discover a 2 to 4-fold decrease in 5hmC in promoter regions of the five TSGs and H19 ICR that are hypermethylated by mutant KRAS expression ( Figures 4B and S3B ). Because traditional bisulfite sequencing cannot distinguish 5mC and 5hmC , we used Tet-assisted bisulfite sequencing (TAB-seq) (Yu et al., 2012) to identify specific 5hmC modifications in V1 and R2 cells. As shown in Figure 4C , 5hmC modifications were decreased from 8.1% (V1) to 4.5 % (R2) in the DAPK promoter, 9.8% (V1) to 3.9% (R2) in the MGMT promoter and 9.2% (V1) to 4.1% (R2) in the DUOX1 promoter, respectively.
Given the finding that KRAS activation inhibits TET1 expression, the decrease of 5hmC in targeted genes might be due to reduced chromatin association with TET1. By TET1 chromatin immunoprecipitation (ChIP), we found that TET1 chromatin occupancy was reduced at the examined promoters in all KRAS cell lines ( Figures 4D and S3C ). To test whether loss of TET1 was responsible for gene silencing and cellular transformation observed in KRAS cells, we reintroduced TET1 expression in KRAS cell lines. As shown in Figures S3D and S3E , we ectopically expressed the catalytic domain of human TET1 (aa 1418-2136) (Guo et al., 2011) at a mRNA level equivalent that of endogenous TET1 in vector cells without affecting cell viability. This reactivated expression of all five TSGs and H19, which had been silenced by KRAS ( Figures 4E and S3F) . Moreover, as shown in Figure 4F , restoration of TET1 expression also suppressed KRAS-mediated transformation. Thus, TET1 suppression is required to maintain TSG silencing and transformation in KRAS cells.
Loss of Tet1 Expression is Associated with Decreased 5hmC and Increased 5mC Content in Kras-Transformed NIH3T3 Cells
Previous work showed that oncogenic Kras expression caused methylation-mediated silencing of TSGs in NIH3T3 mouse fibroblast cells in a manner that depends on Dnmt1 and other positively acting factors (Gazin et al., 2007) . We hypothesized that suppression of Tet1-mediated DNA modifications might underlie Kras-driven hypermethylation in this system. As shown in Figures 5A and S4A , Dnmt1 was increased 2-fold in oncogenic Krastransformed NIH3T3 (Kras) cells. In addition, Tet1 was decreased 2-fold while Tet2 and Tet3 were also modestly down-regulated in Kras cells. At the genome level, Kras activation resulted in a nearly 2-fold increase in 5mC accompanied by a 30% decrease of 5hmC levels ( Figure 5B ). Kras-dependent hypermethylation and silencing in NIH3T3 cells includes the Fas, Sfrp1 and Lox genes (Gazin et al., 2007) . As shown in Figures 5C and S4A , the mRNA expression of these genes was nearly extinguished by Kras activation. To gain further insight into the dynamics of 5mC and 5hmC, we compared 5mC and 5hmC content in promoter regions in parallel. Our data showed intense methylation increases from 0% 5mC to 80% 5mC concomitant with a 4-fold 5hmC decrease in Kras cells compared to NIH3T3 cells ( Figures 5D, S4B and S4C ). As shown in Figures 5E and S4D , bisulfite sequencing and TAB-seq indicated that there were few or no 5mC modifications in the examined promoters in NIH3T3 cells while Ras activation up-regulated methylation to greater than 70%. Increases in 5mC were accompanied by up to 3-fold reduction in 5hmC in Kras cells. The Fas promoter has been reported to be unmethylated in nontransformed NIH3T3 cells (Gazin et al., 2007) . However, all 7 interrogated CpG sties in the Fas promoter were 95-100% in the 5hmC state in NIH3T3 cells. Upon Kras transformation, these CpG sites were converted to 50-100% 5mC. These data indicate that NIH3T3 cells employ a strong Tet-dependent DNA modification activity to maintain TSG promoters at low methylation status. Consistent with this interpretation, Tet1 is highly associated with Fas, Sfrp1 and Lox promoters in NIH3T3 cells and is largely evacuated from them in Kras-transformed NIH3T3 cells ( Figures 5F and S4E ). Figures 6A and S5A , Erk pathway activity is required for down-regulation of Tet1 in Kras-transformed NIH3T3 cells. Erk inhibition reactivated silenced TSGs ( Figure  6B ) and reduced colony formation ( Figures S5B and 6C) , while Akt inhibition showed no significant changes ( Figures 6B and 6C ). Reintroduction of TET1 expression was also sufficient to increase expression of Fas, Sfrp1 and Lox nearly 3-fold without affecting cell viability ( Figure 6D and S5C) . By reintroducing TET1 expression to Kras-transformed NIH3T3 cells, we greatly reduced colony-forming ability ( Figure 6E ).
As shown in
Thus, in NIH3T3 and HBEC3 cells, KRAS activation suppresses TET1 transcription through the ERK signaling pathway. Reduction of TET1 led to decreased 5hmC, increased 5mC levels, and silencing of TSG promoter regions associated with reduced TET1 chromatin occupancy. Restoration of TET1 by ERK pathway inhibition or reintroducing TET1 gene expression reactivated silenced TSGs and reduced colony formation. These data identify TET1 in an essential axis of KRAS-ERK-TSG hypermethylation in the transition from an immortalized cell to a malignant cell.
Knocking down TET1 restores colony-forming ability to KRAS-depleted H1299 cancer cells
To dissect the connection between KRAS and TET1 in fully malignant cells, we used siRNA treatment to determine TET1 expression after KRAS depletion in H1299 lung cancer cells. After treating with KRAS siRNA for 2 days, TET1 mRNA and protein increased nearly 2-fold compared to mock-transfected cells or control siRNA, while DNMT1 expression stayed the same ( Figure 7A ). As shown in Figure S6A , KRAS-mediated suppression of TET1 was also observed in HepG2 hepatoma cancer cells, indicating that negative regulation by KRAS of TET1 is not cell type-specific. In agreement with our findings in HBEC3 and NIH3T3 cells, inhibition of the ERK signaling pathway reactivated TET1 expression, whereas AKT pathway inhibition failed to produce this effect ( Figure 7B ). Moreover, KRAS knockdown inhibited colony-forming activities ( Figure 7C ), indicating that H1299 cells are addicted to KRAS expression. To determine whether TET1 is functionally important in KRAS knockdown cells, we treated cells with KRAS siRNA, TET1 siRNA or combined KRAS and TET1 siRNAs. We confirmed that TET1 knockdown was sufficient to prevent TET1 induction in KRAS/TET1 double knockdown cells ( Figure 7D and S6B) . Colony-forming assays performed with siRNA-treated cells indicated that TET1 knockdown in a cell depleted for KRAS is sufficient to rescue the inhibition of colony formation by loss of KRAS ( Figure 7E) . Thus, despite the many targets downstream of the PI3K-AKT and RAF-MEK-ERK cascades and the complexity of RAS-driven oncogenesis, TET1 suppression is sufficient to restore H1299 malignancy.
Discussion
Cancers with RAS activation exhibit aberrant promoter hypermethylation and transcriptional silencing of TSGs. Sustained epigenetic repression of TSGs not only promotes tumor initiation, but also maintains their survival and malignant properties. Based on the fact that DNMT isozymes convert cytosine bases to 5mC, DNMT enzymes, especially DNMT1 (Gazin et al., 2007) , are considered the main effectors that drive DNA hypermethylation during RAS-induced tumorigenesis. This work reveals that suppression of TET1 expression is essential for KRAS-induced DNA hypermethylation in cancer cells ( Figure 7F ).
In the Kras-transformed NIH3T3 system, when PI3K and MEK are inhibited, the Fas and Sfrp1 promoters are rapidly demethylated even when an inhibitor of DNA replication is applied (Wajapeyee et al., 2013) . These data implied a mechanism for active DNA demethylation, which had not been identified. It has been reported that reduced TET gene expression and genomic 5hmC levels are common features of cellular transformation and that this can be induced by BRAF expression (Kudo et al., 2012) . Here we show that MEK activity is part of a specific signal transduction pathway required for TET1 suppression and for the KRAS program of TSG hypermethylation. As shown in Figure 5E , the ability of apoptosis-proficient NIH3T3 cells to maintain expression of Fas is so important that the Fas promoter is apparently kept in a 5hmC-modified state by Tet1 so that it cannot be silenced by methylation. Kras transformation depletes Tet1 and allows Dnmt enzymes to convert nonmodified CpG dinucleotides to 5mCpG dinucleotides at the Fas promoter.
Although similar KRAS-mediated TET1 suppression was found in HBEC3 and NIH3T3 cells, there are two important differences. First, decreased Tet1 was accompanied by increased Dnmt1 in Kras-transformed NIH3T3 cells, while TET1 was reduced without DNMT1 alteration in KRAS-transformed HBEC3 cells. These cell-type specific effects indicate that KRAS can regulate dynamic DNA methylation by inhibiting TET1 expression alone or by further coupling with increased DNMT1. Further studies should reveal whether TET1 reduction and DNMT1 induction by KRAS activation work collaboratively or independently on target genes to cause promoter hypermethylation during tumorigenesis. Second, a significant reduction in genomic 5hmC was observed in Kras-transformed NIH3T3 cells but not in HBEC3 cells, suggesting that extinguishing TET1 expression may be insufficient to reduce global 5hmC. This may be the case because TET proteins regulate 5mC conversion to 5hmC at distinct genomic loci. TET1 localizes to CpG-rich promoters via its CXXC domain (Huang et al., 2014; Xu et al., 2011) . However, TET2, which lacks the CXXC domain, associates primarily with gene bodies (Huang et al., 2014) . Indeed, in ESC, Tet2 knockdown causes a greater reduction in genomic 5hmC levels than Tet1 knockdown (Huang et al., 2014) . In addition, TET family proteins may be partially redundant with the potential for TET2 and TET3 to maintain genomic 5hmC levels when TET1 is not expressed. Consistent with this hypothesis, double depletion of Tet1 and Tet2 more significantly reduces 5hmC levels than individual depletion (Dawlaty et al., 2013; Koh et al., 2011) .
The architectural transcription factor high mobility group AT-hook 2 (HMGA2) acts as a repressor of TET1 expression in a metastatic bone-tropic breast cancer cell line derived from MDA-MB-231 (Sun et al., 2013) . Because HMGA2 expression is regulated by BRAF, ERK and let-7 in this cell line (Dangi-Garimella et al., 2009) , it was possible that alteration of HMGA2 might be a common feature of KRAS-driven TET1 suppression. However, neither KRAS transformation in HBEC3 ( Figure S2D ) or NIH3T3 cells or KRAS knockdown in H1299 or HepG2 cells altered expression of HMGA2, LIN28, SNAIL, HOXA7 or HOXA9 genes (data not shown).
Though it is possible for oncogenes to be dispensable after establishment of neoplastic transformation, oncogene addiction (Weinstein, 2002) is common and well documented in RAS-dependent malignancies (Chin et al., 1999; Singh et al., 2009) , and depends on the RAS-driven DNA hypermethylation phenotype (Wajapeyee et al., 2013) . In our study, because TET1 re-expression blocks transformation and because TET1 knockdown can allow KRAS knockdown cells to retain a malignant phenotype, we identified TET1 repression as a critical component of the RAS program. Several inhibitors of the EGFR-RAS-RAF-MEK-ERK axis are under development (Downward, 2003; Engelman et al., 2008; Karapetis et al., 2008; Pao and Chmielecki, 2010) . Because these drugs may depend on re-activating TET1 expression for efficacy, TET1 re-repression or increased 5hmC may serve as biomarkers of functional reversion of RAS transformation.
Experimental Procedures
Cell Culture HBEC3 cells and stable cell lines were grown in KSFM media supplemented with bovine pituitary extract and recombinant human EGF unless specific indicated. NIH3T3 cells (CRL-1658, ATCC), Kras-transformed NIH3T3 cells (CRL-6361, ATCC) and HepG2 cells were grown in DMEM media with 10% FBS. H1299 cells were grown in RPMI-1640 media with 10% FBS.
Establishment of Stable Cell Lines
To establish oncogenic KRAS-expressing stable lines in HBEC3 cells, a full-length human KRAS-G12V cDNA clone (gift of Dr. John Minna) was used as template to generate a KRAS-G12V construct with an N-terminal myc-tag. For transient TET1 reintroduction, a catalytic domain of human TET1 cDNA clone (plasmid 39454, Addgene) (Guo et al., 2011) was used as template to generate a TET1 construct with an N-terminal myc-tag. PCR fragments were first T/A cloned into pGEM-Teasy vector (Promega) and then subcloned into pLenti6/V5 vector (Invitrogen). Viral production and transduction was performed using ViralPower Bsd Lentiviral Support Kit (Invitrogen). Monoclonal cell lines were selected by serial dilution in 96-well plates with 5 μg/ml Blasticidin (Invitrogen). Primer pairs used for plasmid construction are provided in Table S2 .
DNA Dot Blot Assays
For global 5mC and 5hmC levels, DNA dot blots were performed with a 96-well manifold. Genomic DNA was extracted using DNeasy Blood & Tissue Kit (Qiagen). 1 μg genomic DNA and serial 2-fold dilutions were mixed with 0.4 M NaOH, 10 mM EDTA and denatured at 100°C for 10 min. Samples were then chilled on ice and neutralized with an equal volume of 2 M ammonium acetate pH 7.0 and loaded onto a 20× SSC rinsed Hybond-ECL nitrocellulose membrane. 5mC and 5hmC were detected using specific antibodies (5mC, 39769, Active motif; 5hmC, BI-MECY, Eurogentec) and visualized by SuperSignal West Femto Substrate (Thermo Scientific).
MeDIP and hMeDIP
Promoter methylation analysis was performed using MethylMiner Methylated DNA Enrichment Kit (Invitrogen) and promoter hydroxymethylation analysis was performed using HydroxyMethyl Collector (Active Motif). Genomic DNA was first fragmented by sonication to an average size of 400 bp. Methylated DNA or hydroxymethylated DNA was captured and eluated following the manufacturers' protocols. 5mC and 5hmC levels were analyzed using specific primer sets with qPCR (Table S2 and S3). 10% of input DNA was used as a control. All data were collected from 3 independent experiments.
Bisulfite Sequencing
For 5mC detection, genomic DNA was treated with bisulfite using EpiTect Bisulfite kit (Qiagen). Bisulfite treated DNA was then used as a template and PCR was performed using specific primer pairs (Table S2 and S3 ). Final PCR products were gel purified and cloned into the pGEM-T easy vector. Independent clones were subjected to sequencing. For 5hmC detection, genomic DNA was applied to 5hmC TAB-seq Kit (WiseGene) following the manufacturer protocol prior to bisulfite coversion.
ChIP
ChIP was performed with Magna ChIP HiSens chromatin immunoprecipitation kit (Millipore), TET1 antibody (09-872, Millipore), and analyzed using qPCR (Table S2 and S3). 10% of input DNA was used as a control. All data were collected from 3 independent experiments.
siRNA Transfection
Cells were transfected with 10 nM siRNA using the Lipofectamine RNAiMAX Reagent (Invitrogen). siRNAs were purchased from PreDesigned Oligo Sets (Integrated DNA Technologies), including siControl (DS NC1); siKRAS-1 (N004985.12.3); siKRAS-2 (N004985.12.5); siTET1-1 (N030625.12.1) and siTET1-2 (N030625.12.2).
Statistical Analysis
All data were presented as mean ± SD. Paired Student's t tests or one-way ANOVA was used to calculate P-value and determine significance. P-values below 0.05 were considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. (F) Adherent and soft-agar colony formation after 5-aza-dC treatment indicate that KRAS transformation depends on the hypermethylation phenotype. Cells were pre-treated with 100 nM 5-aza-dC for 5 days and then tested for colony formation. All data are presented as mean ± SD. ns, no significant difference; *, p< 0.05; **, p < 0.01; ***, p < 0.001 in comparison to V1 cells or DMSO treated control. See also Figure S1 . (D) Adherent and soft-agar colony formation after ERK pathway or AKT pathway inhibition indicate that cellular transformation is mediated by the ERK pathway. Cells were pre-treated with inhibitors for 6 days and then tested for colony formation. All data are presented as mean ± SD. ns, no significant difference; **, p < 0.01; ***, p < 0.001 in comparison to V1 cells or DMSO treated control. See also Figure S2 . (F) Adherent and soft-agar colony formation after TET1 viral transduction indicate that TET1 re-expression reverts the transformed phenotype. All data are presented as mean ± SD. ns, no significant difference; *, p < 0.05; **, p < 0.01;***, p < 0.001 in comparison to V1 cells or vector virus control. See also Figure S3 . (E) Bisulfite sequencing for 5mC and TAB-seq for 5hmC. The percentages of 5mC or 5hmC were indicated. (F) Tet1 chromatin occupancy was analyzed using Tet1 ChIP and qPCR. The data indicate that Kras transformation depresses Fas expression by converting the promoter from a 5hmC state to a 5mC state due to depletion of Tet1. All data are presented as mean ± SD. **, p < 0.01; ***, p < 0.001 in comparison to NIH3T3 cells. See also Figure S4 .
Figure 6. Kras Promotes Transformation by Inhibiting Tet1 Expression
(A) After 25 μM PD98059 or 2.5 μM LY294002 treatment for 4 days, protein levels of Dnmt1 and Tet1 were determined by western blotting. (B) After Erk pathway or Akt pathway inhibition, mRNA levels were analyzed by RT-qPCR and normalized to DMSO control. (C) Adherent and soft-agar colony formation after Erk pathway or Akt pathway inhibition indicate that cellular transformation is mediated by the ERK pathway in KRAS-transformed NIH3T3 cells. Cells were pre-treated with inhibitors for 4 days and then tested for colony formation. (D) After TET1 viral transduction for 6 days, mRNA levels were analyzed by RT-qPCR and normalized to vector viral transduction control. (E) Adherent and soft-agar colony formation after TET1 viral transduction indicate that TET1 re-expression reverts Kras-mediated malignancy. All data are presented as mean ± SD. ns, no significant difference; **, p < 0.01; ***, p < 0.001 in comparison to DMSO treated control or vector virus control. See also Figure S5 . (A) After 10 μM KRAS siRNA treatment for 2 days, mRNA levels were determined by RT-qPCR and normalized to mock control without adding siRNA. Protein levels of TET1 and DNMT1 were determined by western blotting. (B) After 20 μM PD98059 or 5 μM LY294002 treatment for 2 days, protein levels were determined by western blotting. (C) Adherent and soft-agar colony formation after KRAS siRNA treatment. (D) Protein levels were determined by western blotting after siRNA treatments. (E) Adherent and soft-agar colony formation after indicated siRNA treatments. The data indicate that KRAS becomes dispensable if TET1 is knocked down. All data are presented as mean ± SD. ns, no significant difference; ***, p < 0.001 in comparison to mock cells or siControl treated cells. (F) Essential role of TET1 suppression for RAS-mediated DNA hypermethylation and cellular transformation. TET1 modulates epigenetic and transcriptional regulation via hydroxylation of 5mC and subsequent DNA demethylation. TET1 targets CpG-rich promoters of TSGs to prevent DNA hypermethylation. The KRAS-ERK signaling pathway suppresses TET1 transcription. In KRAS-transformed cells, TET1 suppression decreases
